Polysaccharide glucomannan isolated from Heterodermia obscurata attenuates acute and chronic pain in mice  by Córdova, Marina M. et al.
Carbohydrate Polymers 92 (2013) 2058– 2064
Contents lists available at SciVerse ScienceDirect
Carbohydrate  Polymers
jou rn al hom epa ge: www.elsev ier .com/ locate /carbpol
Polysaccharide  glucomannan  isolated  from  Heterodermia  obscurata  attenuates
acute  and  chronic  pain  in  mice
Marina  M.  Córdovaa,b, Daniel  F. Martinsa,b, Morgana  D.  Silvaa,b, Cristiane  H. Baggioc,
Elaine R.  Carbonerod, Andrea  C.  Ruthesd, Marcello  Iacominid, Adair  R.S.  Santosa,b,∗
a Laboratório de Neurobiologia da Dor e Inﬂamac¸ ão,  Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina,
Florianópolis,  SC, Brazil
b Pós-Graduac¸ ão em Neurociências, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil
c Departamento de Farmacologia, Universidade Federal do  Paraná, Curitiba, PR, Brazil
d Departamento de Bioquímica e Biologia Molecular, Universidade Federal do  Paraná, Curitiba, PR, Brazil
a  r  t  i  c  l  e  i  n f  o
Article history:
Received 3 September 2012
Received in revised form 29 October 2012
Accepted 13 November 2012
Available online 23 November 2012
Keywords:
Polysaccharide
Nociception
Glutamate
Pro-inﬂammatory cytokines
Neuropathic pain
a  b  s  t  r a  c t
Glucomannan  (GM)  is a  polysaccharide obtained  from  Heterodermia obscurata  lichens. The present  study
was  conducted  to elucidate the  antinociceptive  effect  of GM  in  behavioural  models  of acute and  chronic
pain  in mice. GM  reduced  mechanical  allodynia and the  levels  of interleukin  1- (IL-1)  in spinal cord and
nerve  in the  partial  sciatic nerve  ligation (PSNL)  model.  Systemic  treatment  with  GM  inhibited the noci-
ception  induced  by  intraplantar  injection of glutamate  and  by  intrathecal injection  of N-methyl-d-aspartic
acid  (NMDA),  (±)-1-aminocyclopentane-trans-1,3-dicarboxylic  acid  (trans-ACPD),  tumour  necrosis fac-
tor    (TNF-)  and  IL-1.  Taken together,  our data  demonstrate  that  GM has signiﬁcant antinociceptive
effect  in acute  and  chronic pain, suggesting  a potential  interest  in the  development  of new  clinically
relevant  drugs for  the  management  of pain.
© 2012 Elsevier Ltd. 
1. Introduction
The sensation of pain alerts us to real or impending injury
and triggers an appropriate protective response. Unfortunately,
pain often outlives its usefulness as a  warning system and instead
becomes chronic and debilitating (Julius & Basbaum, 2001). Altered
activity of spinal and/or brain neurons relevant to the pain pathway,
and also of primary sensory nociceptors, leads to chronic neuro-
pathic pain (Milligan & Watkins, 2009). However, data from clinical
trials and experience indicate that treatment of neuropathic pain
presents a considerable challenge, because many patients do  not
experience sufﬁcient pain relief. This may  be due to  the heterogene-
ity of neuropathic pain mechanisms, and the frequently coexisting
psychological and emotional aspects of chronic pain (Baron, Binder,
Abbreviations: CNS, central nervous system; DRG, dorsal root ganglion; GM,  glu-
comannam; IL-1, interleukin 1-; NMDA, N-methyl-d-aspartic acid; PSNL, partial
sciatic nerve ligation; PMSF, phenylmethylsulphonyl ﬂuoride; TNF-, tumour necro-
sis factor ; trans-ACPD, (±)-1-aminocyclopentane-trans-1,3-dicarboxylic acid.
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& Wasner, 2010). For this reason, the development of analgesic
drugs requires the testing of new therapeutic sources and with few
side effects.
Physicians have long relied on natural products (e.g., chemical
compounds produced by animals, plants, and microorganisms) to
treat diseases. Natural products are  directly or indirectly respon-
sible for approximately 50% of all drugs currently in use (Koehn
& Carter, 2005). In this respect, some lichenized fungal species
have been used in traditional medicine and it was  found con-
siderable quantities of polysaccharides (Baron, Iacomini, Fant, &
Gorin, 1991; Vartia, 1973). Many of them are known to exert
anti-tumour, antiviral, immunostimulating or memory-enhancing
properties among other biological activities, exhibiting low tox-
icity levels (Olafsdóttir & Ingólfsdóttir, 2001). Also, it has been
shown that the polysaccharides have anti-inﬂammatory and anal-
gesic effects (Baggio et al., 2010; Komura et al., 2010; Smiderle,
Olsen, Carbonero, Marcon, et al., 2008; Smiderle, Olsen, Carbonero,
Baggio, et al., 2008). Among these polysaccharides, a glucomannan
(GM) isolated from the highly branched lichen species Heteroder-
mia obscurata presented antinociceptive and anti-inﬂammatory
effects, with dose-dependent inhibition of acetic acid-induced vis-
ceral pain, and also reduction of leucocyte migration (Pereira et al.,
2010). However, the mechanisms underlying these effects remain
unclear.
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In the present study, we evaluated the antinociceptive role of
GM, using behavioural models of acute and chronic pain in mice.
We investigated the effects of GM on the mechanical allodynia
response induced by PSNL (neuropathic pain model) and the levels
of pro-inﬂammatory cytokines (IL-1 and TNF-) in the spinal cord
and sciatic nerve. To support the possible involvement of the gluta-
matergic system and pro-inﬂammatory cytokines in  GM-mediated
analgesia, we also investigated the effects of GM on the nociceptive
response induced by  intrathecal injection (i.t.) of ionotropic (NMDA
and kainate) and metabotropic (trans-ACPD) glutamate receptor
agonists, and also of IL-1 and TNF-.
2. Materials and methods
2.1.  Animals
Male Swiss mice (25–35 g) were obtained from the Federal
University of Santa Catarina. The mice were maintained at con-
stant room temperature (22 ± 2 ◦C)  under a 12-h light/dark cycle
(lights on at 6:00 AM), with access to food and water ad libitum.
Mice (6–10 animals per group) were used only once and were
acclimatized to the laboratory for at least 1 h before testing. All
testing was conducted during the light cycle. The experimental
protocol was approved by the Institutional Ethics Committee for
Animal Research of the Federal University of Santa Catarina (pro-
tocol number 23080.005796/2010-20/UFSC). All  experiments were
conducted in accordance with the current guidelines for the care of
laboratory animals and the ethical guidelines for the investigation
of experimental pain in  conscious animals (Zimmermann, 1983).
The number of animals and the intensities of noxious stimuli used
were the minimum necessary to demonstrate a consistent effect of
the treatment.
2.2. Isolation and characterization of polysaccharide
The polysaccharide GM was extracted, isolated and structurally
characterized by Pereira and colleagues, exactly as described in a
previous work (Pereira et al., 2010). The dried lichen thallus of H.
obscurata (30.3 g)  was ﬁrst extracted with acetone at 50 ◦C for 6 h
(2×) and then with EtOH at 60 ◦C for 6 h (2×), in order to extract
low molecular components. The defatted product was  then sub-
mitted to successive aqueous (100 ◦C) and alkaline extractions (2%
and 10% aq. KOH at 100 ◦C for 6 h,  each), and the extracted polysac-
charides were recovered by EtOH precipitation (aqueous extract)
or after dialysis (HOAc neutralized alkaline extracts), giving frac-
tions W,  K2, and K10  respectively. The crude fractions obtained
from aqueous (W)  and alkaline extractions (K2 and K10) were
submitted to freezing followed by  gentle thawing at 4 ◦C (Gorin
& Iacomini, 1984), furnishing cold-water soluble (SW, SK2, and
SK10) and insoluble polysaccharides, which were separated by cen-
trifugation (8500 rpm, 20 min, 25 ◦C). The water-soluble fractions
were then treated with Fehling solution (Jones & Stoodley, 1965)
and the resulting insoluble Cu2+ complexes were isolated by cen-
trifugation under the above conditions. The respective complexes
(FP-W, FP-K2, and FP-K10), were each neutralized with AcOH, dia-
lyzed against tap H2O and deionized with mixed ion exchange
resins.
The presence of glucomannan (GM) was detected at fraction FP-
K2 (Pereira et al., 2010), and the characterization of the structure of
GM was based on its monosaccharide composition, methylation,
partial acid hydrolysis, and NMR  spectroscopic analysis (Pereira
et al., 2010). The glucomannan consists of a main chain of (1→6)-
linked -d-mannopyranosyl units, almost all being substituted
at O-2 with -d-glucopyranosyl, -d-mannopyranosyl, and 4-O-
substituted -Manp groups (Pereira et al., 2010).
2.3. Partial sciatic nerve ligation (PSNL)
Surgical procedures were performed under deep anaesthesia
induced by a premixed solution containing ketamine (80 mg/kg,
i.p.) and xylazine (10 mg/kg, i.p.), and maintained with isoﬂurane
(2–3% in 100% O2). Partial ligation of the sciatic nerve was  per-
formed by tying the distal 1/3 to  1/2 of the dorsal portion of  the
sciatic nerve (Malmberg & Basbaum, 1998). In  sham group, the sci-
atic nerve was exposed without ligation. All  wounds were closed
and covered with iodine solution. Sham-operated mice received
only saline (10 mL/kg, i.p.) and the operated mice were randomly
divided into control and treatment groups, which received saline
(10 mL/kg, i.p.) and GM (100 mg/kg, i.p.), respectively, 7 days after
surgery. The mechanical allodynia response was recorded before
surgery (B),  and immediately before (0  h) and after (0.5 h,  1 h,  2 h,
4 h,  and 24 h) treatment to verify the time-course effect of  GM.
To investigate the effects of long-term treatment with GM on the
mechanical allodynia response, GM (100 mg/kg) was  administered
i.p. once a  day for 13 days. The mechanical allodynia response was
evaluated 0.5 h after treatment. Repeated treatment was extended
from the 7th to the 13th day after ligation, and was then interrupted
for 5 days. After this, it was  re-initiated to  assess the development
of possible GM tolerance.
The mechanical allodynia response was  evaluated using cali-
brated von Frey ﬁlaments (Stoelting, Chicago, IL), according to the
methodology described by Chaplan, Bach, Pogrel, Chung, and Yaksh
(1994), with minor modiﬁcations. The paw withdrawal threshold
was determined using an adaptation of the Dixon up–down method
(Chaplan et al., 1994). Mice were further acclimatized in  individual
clear boxes (9 cm × 7 cm × 11 cm)  on an elevated wire-mesh plat-
form, to allow access to the ventral surface of the hind paws. The von
Frey ﬁlaments (0.02–4.0 g) were presented perpendicularly to the
plantar surface of the selected hind paw, and held in  this position
with enough force to cause a  slight bend in  the ﬁlament. Positive
responses included an abrupt withdrawal of the hind paw from the
stimulus, or ﬂinching behaviour immediately following removal of
the stimulus.
2.4.  Determination of pro-inﬂammatory cytokine levels in the
sciatic  nerve and spinal cord of the PSNL model
In this series of experiments, we examined the levels of  IL-1
and TNF- in the sciatic nerve and spinal cord of the PSNL model of
neuropathic pain. Brieﬂy, at the end of the experiment described
above, the animals were anaesthetized with isoﬂurane and killed
by decapitation and the sciatic nerve and lumbar portion of  the
spinal cord (L1–L6) were removed. The tissues were homogenized
with a  PBS solution containing Tween 20 (0.05%), 0.1 mM  phenyl-
methylsulphonyl ﬂuoride (PMSF), 10 mM EDTA, 2 ng/mL aprotinin,
and 0.1 mM benzemethonium chloride and centrifuged at 3000 × g
for 10 min  at 4 ◦C. The supernatant obtained was  stored at (70 ◦C
until further analysis and the total protein content was measured
using the Bradford method. The levels of TNF- and IL-1 were
determined using sample aliquots of 100 L and mouse cytokine
ELISA kits from R&D Systems (Minneapolis, MN,  USA), according to
the manufacturer’s instructions.
2.5.  Measurement of locomotor activity
To evaluate the possible nonspeciﬁc muscle-relaxant or seda-
tive effects of GM,  mice were submitted to  the rota-rod test, with
minor modiﬁcations (Scheidt et al., 2002). The apparatus consisted
of a  bar with a  diameter of 2.5 cm,  subdivided into 4 compartments
by discs 25 cm in diameter. The bar rotated at a constant speed
of 17 revolutions/min. The animals were selected 24 h previously
by eliminating those mice which did not remain on the bar for 2
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consecutive periods of 60 s. Mice were treated by  the i.p. route with
GM (50 mg/kg and 100 mg/kg) or saline (10 mL/kg) 0.5  h before
being tested. The results are expressed as the time (s) for which
animals remained on the rota-rod. The cut-off time used was 60 s.
2.6. Glutamate-induced nociception
Glutamate (20 L; 20 mol  per paw, prepared in  isotonic saline
solution, with the pH adjusted to  7.4 by  the addition of NaOH)
was injected intraplantarly into the right hind paw. Animals were
observed individually for 15 min  after glutamate injection (Meotti
et al., 2009). The amount of time spent licking the injected paw was
recorded with a chronometer, and was considered to be indicative
of nociception. Animals were treated with GM (10–100 mg/kg, i.p.)
0.5 h before glutamate injection. Control animals received a  similar
volume of saline (10 mL/kg, i.p.).
2.7. Intrathecal injection of excitatory amino acids and
pro-inﬂammatory cytokines to induce pain behaviour in mice
Intrathecal  injections were given to fully conscious mice. Brieﬂy,
the animals were manually restrained, and a  30-gauge needle
connected by a polyethylene tube to  a 25 L Hamilton gas-tight
syringe (Hamilton, Birmingham, UK) was inserted through the skin
and between the vertebrae into the subdural space of the L5–L6
spinal segments. Intrathecal injections (5 L/site) were adminis-
tered over a period of 5 s (Hylden & Wilcox, 1980). Biting behaviour
was deﬁned as a single head movement directed at the ﬂanks
or hind limbs, resulting in contact of the animal’s snout with
the target organ. The nociceptive response was elicited by NMDA
(450 pmol/site, a selective agonist of the NMDA glutamatergic
ionotropic receptor), kainate (110 pmol/site, a  selective agonist of
the kainate subtype of glutamatergic ionotropic receptors), and
trans-ACPD (50 nmol/site, a  non-selective agonist of metabotropic
glutamate receptors, which is active at group I  and group II) (Scheidt
et al., 2002), TNF- (0.1 pmol/site) and IL-1 (1 pmol/site) or saline
(5 L/site, i.t.) (Paszcuk et al., 2007). The amount of time the ani-
mal spent biting or licking the caudal region was taken as evidence
of nociception and was evaluated following local post injections of
the following agonists: NMDA (5 min), kainate (4 min), and trans-
ACPD (Scheidt et al., 2002) TNF-, and IL-1 (15 min) (Paszcuk et al.,
2007). Animals received GM (100 mg/kg, i.p.) 0.5  h before intrathe-
cal injection of 5 L  of the drugs, while control animals received a
similar volume of saline (10 mL/kg, i.p.).
2.8.  Drugs and reagents
The  following substances were employed: l-glutamic acid
hydrochloride (glutamate) from Sigma Chemical Co. (St. Louis,
USA); N-methyl-d-aspartic acid (NMDA), kainite, and (±)-1-
aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD) from
Tocris Cookson Inc. (Ellisville, USA); and interleukin 1- (IL-1) and
tumour necrosis factor  (TNF-) from R&D Systems (Minneapolis,
USA).
2.9. Statistical analysis
The  results are presented as mean ±  standard error of the mean
(SEM), except for the ID50 values (e.g., the dose of GM that
reduced the nociceptive response by 50% in  relation to  the con-
trol value), which are  reported as geometric means accompanied
by their respective 95% conﬁdence limits. The statistical difference
between groups was analyzed by one-way ANOVA followed by the
Newman–Keuls test, or  two-way ANOVA followed by the Bonfer-
roni test for the chronic treatment. Differences were considered
to  be  statistically signiﬁcant at p  <  0.05. The ID50 value was  deter-
mined by nonlinear regression from individual experiments, using
Graph-Pad software (GraphPad Software, San Diego, CA). The per-
centages of inhibition were calculated for the most effective dose
used.
3. Results
3.1. GM decreases the mechanical allodynia response caused by
PSNL
In  comparison with the sham group, the PSNL model showed
reduced paw withdrawal threshold as a measure of the mechan-
ical allodynia response to  von Frey ﬁlament application (Fig. 1).
Acute treatment with GM (100 mg/kg), administered by  the i.p.
route, produced rapid and signiﬁcant (p <  0.001) inhibition of the
mechanical allodynia response induced by PSNL, with 100% rever-
sion at 0.5 h after administration (Fig. 1A). Long-term treatment of
animals with GM (100 mg/kg, i.p.) once a  day markedly reduced
the mechanical allodynia response induced by PSNL, and this effect
was evident until the 13th day of treatment. When the treatment
was suspended for 5 days, the mechanical allodynia response was
re-established, showing that GM treatment did not alter sensory
thresholds (Fig. 1B). On the 19th day, treatment with GM was
restarted. Once again, the mechanical allodynia response was  sig-
niﬁcantly (p < 0.001) reduced, indicating that GM did not lead to the
development of anti-allodynia tolerance, nor  did it alter sensory
thresholds. Analysis of the area under the curve showed that  acute
and long-term treatment of animals with GM signiﬁcantly affected
the mechanical allodynia response of the PSNL group (Fig. 1C and
D). Acute and long-term treatment of sham animals with GM
(100 mg/kg) did not  alter the sensory threshold when compared
to the sham group treated only with saline (data not shown).
3.2.  Effect of GM on levels of pro-inﬂammatory cytokines in the
sciatic  nerve and spinal cord after PSNL
PSNL model signiﬁcantly increased (p <  0.05) the levels of IL-1
and TNF- in  the sciatic nerve and spinal cord when compared with
the sham group (Fig. 2). Long-term treatment with GM (100 mg/kg,
i.p.) markedly reduced the levels of IL-1 in the sciatic nerve
(99 ±  7%), and also in  the spinal cord (63 ± 17%), compared with
the PSNL group (Fig. 2C and D). However, the same dose of GM
(100 mg/kg, i.p.) reduced (although not  signiﬁcantly) the level of
TNF- in  the spinal cord (63 ± 25%; Fig. 2B), but not in the sciatic
nerve (Fig. 2A) when compared with the PSNL group.
3.3.  GM reduces glutamate-induced nociception
GM (10–100 mg/kg, i.p.), administered 0.5 h before testing,
induced a  dose-related inhibition of glutamate-induced nocicep-
tion with ID50 value of 34.1 (26.0–44.6) mg/kg and the inhibition
of 81 ± 5% for the dose of 100 mg/kg (Fig. 3).
3.4. Effect of GM on intrathecal injection of excitatory amino
acids  and pro-inﬂammatory cytokines
Intrathecal injection of NMDA (Fig. 4A), kainate (Fig. 4B), and
trans-ACPD, TNF-, or IL-1 (Fig. 4C) caused signiﬁcant (p < 0.001)
biting behaviour in  mice compared to animals injected intrathe-
cally with saline. In all groups, systemic pre-treatment with
GM (100 mg/kg, i.p.) signiﬁcantly (p <  0.001) reduced the biting
behaviour compared to  mice treated with saline (10 mL/kg, i.p.).
The greatest effect of GM was observed on the pro-inﬂammatory
cytokines and NMDA, with the following inhibition percentages:
TNF- (92 ±  7%), IL-1 (91 ± 5%), NMDA (69 ± 1%), and trans-ACPD
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Fig. 1. Effect of acute (panels A and C, analysis of the area under the curve) or chronic administration (panels B and D, analysis of the area under the curve) of GM (100 mg/kg,
i.p.) on the mechanical allodynia response induced by partial sciatic nerve injury. Each point represents the mean of 8–10 animals; vertical lines indicate the SEM. The
comparison between groups was  performed by  two-way ANOVA followed by  the Bonferroni test. Signiﬁcance levels in comparison with the PSNL group values are denoted
as  follows: *p < 0.05, **p < 0.01, and ***p < 0.001. Signiﬁcance levels in comparison with the sham group values are denoted as follows: #p  <  0.05 and ###p <  0.001. RA indicates
repeated administration.
(71 ± 12%). By contrast, at the same dose, GM had no signiﬁcant
effect on the kainate-mediated biting response (Fig. 4B).
3.5.  Effect of GM on locomotor activity (rota-rod test)
In  comparison with saline administration (control group),
intraperitoneal administration of GM (50 mg/kg and 100 mg/kg),
0.5 h before testing, did not alter the locomotor activity in  the
rota-rod test. The residence time for the control group was  60.0 s,
while the residence times for the groups treated with GM at
doses of 50 mg/kg and 100 mg/kg were 59.7 ±  0.3 s, and 58.8 ± 0.9 s,
respectively.
4. Discussion
Polysaccharides isolated from plants and other natural sources
exert anti-tumour, immunomodulatory, and anticoagulant activ-
ities (Capek et al., 2003; Cipriani et al., 2006; Nergard et al.,
2005; Yamada, 1994). Recently, we demonstrated that many
fungal-derived polysaccharides exhibit important pharmacological
properties, in particular antinociceptive (analgesic) and/or anti-
inﬂammatory activities (Baggio et al., 2010; Carbonero et al., 2008;
Smiderle, Olsen, Carbonero, Marcon, et al., 2008; Smiderle, Olsen,
Carbonero, Baggio, et al., 2008). Interestingly, we also showed that
the polysaccharide glucomannan (GM) isolated from lichenized
fungus H. obscurata reduced the abdominal contractions induced
by  acetic acid, with concomitant reduction of leucocyte migration
to the peritoneal cavity, indicating that it may have antinociceptive
and anti-inﬂammatory properties (Pereira et al., 2010). For this rea-
son, this study aimed to  extend the previous data evaluating the GM
effects on acute and chronic pain in mice.
The inhibitory effects of GM on acetic acid-induced noci-
ception could be attributed, at least in part, to a  reduction of
inﬂammatory mediator’s release. These endogenous inﬂamma-
tory mediators, such as bradykinin, glutamate, prostanoids, and
cytokines (IL-1 and TNF-), are also released during peripheral
nerve injury contributing to  the instigation of neuropathic pain (Ji
& Strichartz, 2004). To investigate the potential and additional anal-
gesic effects of GM,  we used a  preclinical neuropathic pain model.
We observed that acute or long-term administration of  GM sig-
niﬁcantly reduced the mechanical allodynia response induced by
PSNL in mice. This effect was  evident throughout the treatment
regime but, with suspension of treatment for 5 days, hypersen-
sitivity returned to  control levels. However, when treatment was
restarted, we observed that GM again reduced the mechanical allo-
dynia response, indicating that GM does not have a  cumulative
effect. Moreover, it does not lead to the development of  anti-
allodynia tolerance, nor does it alter sensory thresholds.
Additionally, GM also decreases the levels of the pro-
inﬂammatory cytokine IL-1 in the sciatic nerve and spinal cord
after PSNL. However, treatment with GM also inhibited, not sig-
niﬁcantly, the levels of the pro-inﬂammatory cytokine TNF- in
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Fig. 2. Effect of GM (100 mg/kg, i.p.) on the levels of pro-inﬂammatory cytokines induced by partial sciatic nerve injury. Levels of TNF- and IL-1 in the left  sciatic nerve
(panels A and C) and the spinal cord (panels B and D).  Each column represents the mean of 8 animals; vertical lines indicate the SEM. The  comparison between groups was
performed by one-way ANOVA followed by the Newman–Keuls test.  Signiﬁcance levels in comparison with the PSNL group values are denoted by  *p < 0.05. Signiﬁcance levels
in  comparison with the line  group values are denoted as follows: #p < 0.05.
the spinal cord after PSNL. Following injury, activated microglia
and astrocytes in the CNS release large quantities of endogenous
mediators (e.g., glutamate and cytokines), which contribute to
hypersensitivity and the maintenance of neuropathic pain (Austin
& Moalem-Taylor, 2010). Interestingly, systemic treatment with
GM also markedly reduced the nociceptive behaviour induced by
intrathecal injection of IL-1 and TNF-, conﬁrming the involve-
ment of pro-inﬂammatory cytokines in GM antinociception.
The ability of pro-inﬂammatory cytokines (e.g., TNF- and IL-
1) to induce acute nociception when administered intrathecally
has been attributed to the release of glutamate and substance P
(SP) from nociceptive terminals (Austin & Moalem-Taylor, 2010).
Besides, IL-1 has been shown to increase the currents of ionotropic
AMPA and NMDA receptors in  the spinal cord, by increasing the
inﬂux of Ca2+ and activating protein kinase C (PKC), which phospho-
rylates the subunits NR1 and NR2B of NMDA receptors (Brenner, Ji,
Shaffer, & Woolf, 2004; Guo et al., 2002; Kawasaki, Zhang, Cheng,
& Ji, 2008). In the present study, we observed that i.p. admin-
istration of GM inhibited signiﬁcantly and in  a  dose-dependent
manner the acute nociceptive behaviour caused by  i.p. glutamate
injection. This result suggests the involvement of the glutamater-
gic system in the GM mechanism of action. To evaluate which
glutamate receptors (ionotropic or metabotropic) participate in
Fig. 3.  Effect of GM (10–100 mg/kg, i.p.) on  the nociception induced by  i.p. injec-
tion of glutamate. Each column represents the mean of 6–8 animals; vertical lines
indicate the SEM. The comparison between groups was  performed by one-way
ANOVA  followed by  the Newman–Keuls test. Signiﬁcance levels in comparison with
the control group values (closed columns) are denoted by: *p <  0.05,  **p <  0.01, and
***p < 0.001.
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Fig. 4. Effect of GM (100 mg/kg, i.p.) on  the biting response caused by i.t. injection of NMDA (panel A), kainate (panel B), and trans-ACPD, TNF-, or IL-1 (panel C). Each column
represents the mean of 6–8 animals; vertical lines indicate the SEM. The comparison between groups was  performed by  one-way ANOVA followed by the Newman–Keuls
test. Signiﬁcance levels in comparison with the control group values (closed columns) are  denoted by  ***p <  0.001. Signiﬁcance levels in comparison with the saline group
values are denoted as follows: ##p < 0.01 and ###p < 0.001.
the GM-induced antinociception, we performed the intratecal
injection of kainate- and NMDA-receptor agonists. Indeed, the
application of NMDA-receptor antagonists has been shown to  pre-
vent the development of persistent pain (Suzuki, 2009), and also
the central and peripheral sensitization induced by tissue injury
or inﬂammation (Dickenson, Chapman, & Green, 1997; Schaible,
Grubb, Neugebauer, & Oppmann, 1991). Our data demonstrated
that i.p. treatment with GM inhibited the nociception induced by
NMDA receptor agonist, but did not alter the response evoked
by kainate, indicating the regulation of NMDA receptor pathway
by GM.  Differently from a  -glucan isolated from the mushroom
Pleurotus pulmonarius that only inhibited the ionotropic gluta-
mate receptor-induced nociception (Baggio et al., 2010), GM also
reduced the nociception induced by  trans-ACPD (a group I and
group II metabotropic-receptor agonist). However, given that there
is an interaction between ionotropic (NMDA) and metabotropic
receptors in the nociceptive process, additional studies, such as
speciﬁc binding and administration of speciﬁc antagonists, are
required to conﬁrm the interaction of these glutamate receptors
with GM.
Another interesting point is that GM did not cause motor
deﬁcit, nor did it change the locomotor performance of mice
in the rota-rod test. This suggests that GM antinociception is
not associated with nonspeciﬁc effects. In this respect, it is
important to note that various substances (e.g., ketamine, meman-
tine, and amantadine) that antagonize NMDA receptors (Parsons,
2001) or mGluR I (Pietraszek, Nagel, Gravius, Schäfer, & Danysz,
2007; Takahashi & Afford, 2002) produce signiﬁcant changes
in locomotor activity. Our results indicate that GM treatment
produces antinociceptive actions in speciﬁc models of nociception
induced by glutamate, NMDA, and trans-ACPD, without harming
locomotion.
5. Conclusion
In summary, our present data conﬁrm and extend previous
results by demonstrating the signiﬁcant antinociceptive effects of
GM in acute and chronic models of nociception. The antinocicep-
tive effects promoted by  GM seems to involve the cytokine and
glutamate signalling pathways, however, the exactly mechanism
of action remains unclear and further studies are being carried
out. These ﬁndings suggest that GM may  constitute an interest-
ing molecule for the development of a  therapeutically useful drug
to control acute and chronic pain.
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